Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022015
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317)
About the restricted stock incentive plan in 2022
Self inspection report on the trading of company shares by insiders and incentive objects
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) (hereinafter referred to as “the company”) held the 16th meeting of the 7th board of directors and the 9th meeting of the 7th board of supervisors on February 11, 2022, deliberated and adopted the proposal on Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) 2022 restricted stock incentive plan (Draft) and its summary and other proposals, For details, please refer to the company’s publication in the securities times and cninfo (www.cn. Info. Com. CN.) on February 12, 2022 Relevant announcements.
In accordance with the measures for the administration of equity incentive of listed companies (hereinafter referred to as the “measures”), the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – business handling (hereinafter referred to as the “self regulatory guidelines”) and other relevant laws, regulations and the articles of Association, The company has taken sufficient and necessary confidentiality measures for the 2022 restricted stock incentive plan (hereinafter referred to as the “incentive plan”) and registered the insiders of the incentive plan. Through inquiry with China Securities Depository and Clearing Co., Ltd. Shenzhen Branch (hereinafter referred to as “zhongdeng Shenzhen Branch”), The company conducted a self-examination on the trading of the company’s shares by insiders of the incentive plan and incentive objects within 6 months before the public disclosure of the draft incentive plan (i.e. from August 11, 2021 to February 11, 2022, hereinafter referred to as the “self-examination period”), as follows:
1、 Scope and procedure of verification
1. The verification object is the insider and incentive object of the incentive plan.
2. The insiders of the incentive plan have filled in the archives of insiders.
3. The company inquired and confirmed the purchase and sale of the company’s shares during the self inspection period through zhongdeng Shenzhen Branch, and zhongdeng Shenzhen Branch issued the inspection on Shareholding and share change of information disclosure obligor
Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022015
Inquiry certificate and detailed list of changes in shareholders’ shares.
2、 Description of the purchase and sale of the company’s shares by the verification object
According to the inquiry certificate of shareholding and share change of information disclosure obligors and the detailed list of shareholder share change issued by zhongdeng Shenzhen Branch, the stock trading of the verification object is as follows:
1. Purchase and sale of company shares by incentive objects
During the self-examination, a total of 30 incentive objects had stock trading behavior. After verification by the company and according to the written instructions issued by the above incentive objects, the above personnel did not know, nor did they know the inside information of the company’s incentive plan through any insider during the self inspection period, The behavior of buying and selling the company’s shares is an operation carried out by individuals based on the analysis of the company’s publicly disclosed information and their own judgment of the trading situation in the secondary market. There is no case of trading with insider information.
2. Insider trading of company shares
During the self-examination, a total of 2 insiders engaged in stock trading. After verification by the company and according to the written statement issued by the insider of the above-mentioned insider information, the company did not start planning this equity incentive before the above-mentioned personnel bought and sold the company’s shares, and the above-mentioned personnel did not buy and sell the company’s shares during the period when the insider information was informed; During the period of self inspection, the trading behavior is based on the analysis of the company’s publicly disclosed information and its own judgment on the trading market of the secondary market. There is no situation of insider trading due to knowing the insider information. 3、 Verification conclusion
In conclusion, in strict accordance with the provisions of relevant laws, regulations, normative documents and company systems, the company limited the scope of insiders before the public disclosure of the incentive plan, and timely registered the relevant company personnel and intermediaries exposed to the insider information of the incentive plan.
After verification, some of the verification objects have the behavior of buying and selling the company’s shares, which is based on their own judgment of the trading situation in the secondary market, and there is no situation of insider trading due to knowing the insider information. Within 6 months before the announcement of the draft incentive plan, the company has not found that the insider and incentive object of the incentive plan have used the relevant insider information of the incentive plan to buy and sell the company’s shares or disclosed the relevant insider information of the incentive plan, resulting in insider trading. All verification objects comply with the relevant provisions of the administrative measures, and there is no insider trading.
4、 Documents for future reference
Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022015
1. Inquiry certificate of shareholding and share change of information disclosure obligor; 2. Detailed list of changes in shareholders’ shares. It is hereby announced.
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) board of directors March 1, 2002
